 The starting dose for the study will be 0.1 milligram mgkilogram kg s.c. single dose and the highest dose will be 6 mgkg s.c. single dose. Subjects will be admitted to the clinical unit on the day prior to dosing Day -1. On Day 1, each subject will receive a s.c. dose of GSK2330811 or placebo. Subjects will then remain as an in-patient until discharged on Day 8, after assessments have been performed. The duration of the study, including screening, is approximately 19 weeks for Cohorts 1 to 4 and 23 weeks for Cohort 5. 